Columnist Anna Jeter reflects on her mental health needs and various treatment approaches since being diagnosed with PH at ...

gmail.com Background: Vardenafil is a new phosphodiesterase-5 inhibitor that has shown some efficacy in the treatment of pulmonary arterial hypertension (PAH). Objective: To examine the long-term ...

In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

In PATENT-2, clinical worsening (hospitalisation, decrease in 6MWD or persistent worsening of WHO FC due to pulmonary hypertension (PH), start of new PH treatment or death) occurred in 29% of patients ...

Others needing treatment were given continuous intravenous epoprostenol ... In APAH survival rates were 92.3%, 83.8% and 56.9% at 1, 3 and 5 years, respectively, postoperative congenital heart disease ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

4 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center of Lung Research (DZL), Giessen, Germany Until recently, three classes of medical therapy were available for the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.88 and traded ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...